Key facts
- It has raised $220K; the latest was Later Stage VC ($220K) in Mar 2026.
- Notable investors include The University of British Columbia, Victory Square Technologies.
- Status: Privately Held (no backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Insu Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Insu Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Insu Therapeutics
Developer of a buccal drug delivery platform designed to transform injectable peptide medications into oral tablets. The company's platform utilizes mucoadhesive tablets and a mucosal absorption technology to deliver insulin and glucagon-like peptide-1 medications through the oral cavity, bypassing the gastrointestinal tract and liver metabolism issues, enabling diabetic patients to manage chronic conditions without needle injections, refrigeration requirements, or gastrointestinal degradation.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2018
- Website
- insutherapeutics.ca/
- Ownership
- Privately Held (no backing)
Insu Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Insu Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Insu Therapeutics in its N-PORT filings yet. We sweep new filings monthly.